PLUGS POLICY
Patient-centered Laboratory Utilization Guidance Services (PLUGS)
Prenatal Exome and Genome Sequencing Policy
Read the full PLUGS policy
Key Takeaways
- The PLUGS Prenatal Exome and Genome Sequencing Policy provides health plans with an evidence-based foundation for medical policy development.
- The policy translates professional society guidance and published evidence into clearly defined coverage criteria.
- Earlier access to prenatal ES/GS may support diagnosis before birth and inform pregnancy management, delivery planning, neonatal preparedness, and coordinated care.
- Clear criteria can support more consistent coverage decisions, appropriate utilization, and reduced administrative burden.
Translating Prenatal Genomic Sequencing Guidance Into Coverage Policy
Recent guidance from the Society for Maternal-Fetal Medicine (SMFM) reinforces the expanding clinical role of prenatal exome and genome sequencing in selected high-risk pregnancies. While professional society guidance informs clinical practice, health plans must determine how those recommendations should be translated into clear, evidence-based medical policy.
The PLUGS Prenatal Exome and Genome Sequencing Policy bridges that gap by translating current clinical guidance and published evidence into clearly defined medical policy criteria. Developed through a rigorous review of the medical literature and discussion with subject matter experts, the policy provides health plans with an expert-developed, evidence-based foundation they can adopt to streamline medical policy development and support consistent coverage decisions.
Why the PLUGS Prenatal Exome and Genome Sequencing Policy Matters
Patient-centered Laboratory Utilization Guidance Services (PLUGS) is a national laboratory stewardship collaborative that brings together health systems, laboratories, clinicians, payors, industry, and patient advocacy organizations to improve access to medically appropriate laboratory testing.
One of PLUGS' core priorities is Insurance Alignment, developing evidence-based medical policies and best-practice recommendations that help standardize coverage criteria, reduce administrative burden, and improve access to medically necessary testing. This collaborative approach ensures policies are grounded in current evidence while reflecting the practical considerations of real-world coverage policy development.
Key Elements of the Prenatal Exome and Genome Sequencing Policy
The PLUGS Prenatal Exome and Genome Sequencing Policy provides health plans with clearly defined medical policy criteria informed by current clinical guidance. Key elements include:
Defining Appropriate Use
The policy identifies the clinical scenarios where prenatal exome and genome sequencing may be appropriate, helping health plans establish consistent medical necessity criteria for patients most likely to benefit.
Establishing Clear Coverage Criteria
The policy outlines when prenatal exome and genome sequencing should be considered, providing health plans with clear, evidence-based criteria that support consistent coverage decisions.
Supporting Clinically Meaningful Outcomes
The policy focuses on situations where a prenatal genetic diagnosis has the potential to influence clinical decision-making, including pregnancy management, delivery planning, neonatal care, and family counseling.
Promoting Consistent Policy Application
By translating published evidence and professional society recommendations into defined medical policy criteria, the policy helps health plans promote appropriate utilization while reducing unnecessary variation in coverage decisions.
Why Earlier Access to Prenatal Genomic Sequencing Matters for Health Plans
The timing of a diagnosis is often influenced by the timing of access to testing. Medical policies do more than define coverage; rather, they help determine when patients receive answers that can inform clinical care.
For pregnancies with suspected genetic conditions, access to prenatal exome and genome sequencing may provide opportunities to establish a diagnosis before birth rather than once a critically ill newborn requires evaluation. Earlier diagnosis can support informed pregnancy management, delivery planning at an appropriate facility, neonatal preparedness, and coordinated care from the moment a child is born.
For health plans, these decisions have implications beyond medical policy. Earlier diagnostic clarity may reduce diagnostic uncertainty after birth, minimize sequential genetic testing, support more coordinated specialty care, and help clinicians prepare for an infant's medical needs before delivery. While every case is unique, policies that support appropriate use of prenatal genomic sequencing have the potential to shift care from reactive evaluation after birth to proactive planning before delivery.
Continue the Conversation
As prenatal genomic sequencing continues to evolve, GeneDx is committed to helping health plans evaluate emerging clinical evidence and its implications for medical policy. Whether your organization is developing a new prenatal genomic sequencing policy or reassessing existing coverage criteria, the GeneDx Market Access team can help.
Related: Prenatal Genomic Sequencing Resources
Explore real-world examples of how prenatal exome sequencing can help provide answers during pregnancy:
- Jennifer’s story: Second trimester prenatal exome sequencing (PDF)
- Maria’s story: First trimester prenatal exome sequencing (PDF)
Related: Explore the Health Economic Impact of Exome and Genome Sequencing
For health plans interested in the broader economic impact of genomic testing, the SAVES-Kids study examines real-world healthcare utilization and costs following exome and genome sequencing in pediatric populations.
